Taxofen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taxofen

Property Description
Active Ingredient Tamoxifen Citrate (INN)
Form Oral Tablet, Oral Solution (Rx-only)
Pharmacological Class Selective Estrogen Receptor Modulator (SERM)
Origin Synthetic, Non-steroidal compound
General Purpose Targeted endocrine intervention to disrupt growth signals

What Type of Medicine is Taxofen?

Taxofen is a prescription-only (Rx-only) endocrine-targeting medication containing the active ingredient Tamoxifen Citrate (INN). It is chemically a synthetic, non-steroidal compound derived from triphenylethylene. Taxofen is officially classified as a Selective Estrogen Receptor Modulator (SERM). Unlike treatments that fully eliminate the body's estrogen, Tamoxifen selectively interacts with estrogen receptors, managing how cells respond to the hormone. It is a single-ingredient product, with its effects driven entirely by the molecule and its active metabolites, such as endoxifen.

Composition, Forms, and General Therapeutic Role

The therapeutic composition is delivered primarily in an oral dosage form, available as either a tablet or an oral solution. The active Tamoxifen Citrate is compounded with standard pharmaceutical excipients necessary for stability. The general therapeutic purpose of Taxofen is to provide a targeted intervention against diseases where growth is dependent on estrogenic signaling. This mechanism serves as a crucial component of long-term disease management, aimed at disrupting the proliferation signals of hormone-sensitive cells.

The Core Mechanism: Selective Hormone Modulation

The core principle of Tamoxifen's action is its ability to selectively modulate the activity of estrogen receptors. The drug functions by binding to these receptors, effectively competing with and blocking the effects of the body's natural estrogen in certain target tissues. This binding interrupts the cellular signaling pathway that dictates growth and proliferation. This selective activity, where it acts as an antagonist (blocker) in some tissues while retaining weak agonist (stimulant) properties in others, defines its unique pharmacological profile as a SERM.

Regulatory References

  1. Tamoxifen: MedlinePlus Drug Information
  2. Tamoxifen - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Taxofen?

Possible Side Effects and Safety Information

The safety profile of Taxofen (Tamoxifen Citrate) is officially classified by regulatory bodies based on the frequency and the physiological system affected. The most frequently documented adverse reactions often involve hormonal and general systemic effects.

Official Frequency Classifications

Classification Examples of Reactions
Very Common (ge 1/10) Hot flashes (vasodilatation), Nausea, Fluid retention, Vaginal discharge
Common (ge 1/100 to <1/10) Headache, Fatigue, Cataracts, Uterine fibroids, Menstrual irregularities
Uncommon (ge 1/1,000 to <1/100) Pulmonary embolism, Deep vein thrombosis, Endometrial cancer, Leukopenia
Rare (ge 1/10,000 to <1/1,000) Uterine sarcoma, Severe cutaneous reactions (SJS/TEN), Optic neuropathy

Serious Adverse Reactions and Safety Patterns

Official regulatory warnings emphasize the documented risk of serious events. These include Thromboembolic Events, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the risk of Uterine Malignancies, including endometrial cancer and the rarer uterine sarcoma. These serious risks are explicitly documented in regulatory labeling.

Certain safety patterns are linked to the duration of exposure. For example, the incidence of cataracts increases with the duration of Taxofen administration, and the risk of uterine sarcoma is reported to be more frequent among long-term users (typically defined as two years or more).

Population-Specific Safety Notes

Taxofen is contraindicated for use during pregnancy and lactation. Safety and efficacy have not been established in pediatric patients. For women who are premenopausal, the medication may lead to suppression of menstruation.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Taxofen (Tamoxifen Citrate) overdose is defined by specific clinical manifestations and clear, mandated emergency responses outlined in official government documentation.

Documented Clinical Manifestations Official labeling documents specific neurological and systemic signs associated with overdosage. These manifestations include uncontrollable shaking (tremor), reported as a clinical sign, alongside episodes of unsteadiness, and persistent dizziness.

Life-Threatening Manifestation Regulatory Action Mandated
Collapse (loss of consciousness) Immediate call to Emergency Services (e.g., 911).
Seizure (convulsions) Immediate call to Emergency Services (e.g., 911).
Trouble breathing Immediate call to Emergency Services (e.g., 911).
Suspected overdose without severe symptoms Contact the Poison Control Helpline.

Official Management and Emergency Triggers

The official guidance requires urgent medical attention when severe, life-threatening outcomes are present. Emergency medical care must be sought instantly if the individual experiences any of the severe outcomes listed above, or if they cannot be awakened. This guidance is derived from official government prescribing information. A critical constraint in managing overdose is the fact that no specific antidote is known for Taxofen overdosage, as stated in regulatory documents. Consequently, treatment is strictly defined as symptomatic and supportive, addressing the manifestations observed rather than reversing the drug's effects. The regulatory documents define this profile based on the need to manage severe central nervous system effects and respiratory distress.

Therapeutic Uses of Taxofen

What Taxofen Treats: Main Uses and Benefits

The primary therapeutic role of Taxofen (Tamoxifen) is generally applied across therapeutic domains involving hormone-sensitive disease, and is relevant in contexts involving heightened systemic burden for long-term systemic control and risk management. The medication is relevant for managing the underlying condition in patients already diagnosed with Estrogen Receptor-Positive (ER+) breast cancer in both early-stage and metastatic disease settings. It is also commonly used for patients with Ductal Carcinoma In Situ (DCIS), and for individuals considered high-risk seeking to manage the risk of cancer incidence.


Key Therapeutic Contexts

Taxofen is commonly used in an adjuvant setting following primary treatment to address the persistent risk of the disease returning (recurrence). This long-term intervention offers therapeutic support by addressing the risk of relapse and contributes to easing the overall symptom load associated with the condition. The medication may assist with managing the blood cholesterol profile and is commonly used to help with bone mineral density, particularly in postmenopausal patients.

Quick Fact: Relief for Long-Term Risk
Therapeutic Context: Applied in clinical settings that involve long-term systemic control of hormone-driven malignancy risk.
Benefit: Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

  1. DailyMed (NIH/FDA) label for Tamoxifen Citrate tablet

Eligibility and Restrictions for Use

Who Can and Cannot Use Taxofen? — Official Regulatory Information

Category Eligibility Rule Defined by Regulatory Label
Populations Allowed Taxofen is approved for use in adult males and females, including pre-menopausal and post-menopausal women, for the treatment of established Estrogen Receptor-Positive (ER+) breast cancer.
Absolute Contraindications Use is contraindicated in any patient with a known hypersensitivity to the medicine or its ingredients. Pregnant women and nursing mothers must not use Taxofen.
Thromboembolic Restriction For women in the risk reduction setting, use is contraindicated if they have a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or Stroke. It is also prohibited if they require concurrent Warfarin therapy.
Age and Organ Limitations The medicine is not recommended for children and adolescents (under 18) as safety and efficacy are not established. Use in patients with renal or hepatic impairment is not fully characterized, requiring caution.
Reproductive Requirements Women of childbearing potential must exclude pregnancy before beginning therapy and use effective non-hormonal contraception during treatment.

Connection to the overall eligibility profile

Regulatory documents define eligibility based on absolute prohibitions concerning physiological state (pregnancy, lactation) and a history of specific events (thromboembolic history in the risk reduction context). Use is permitted for eligible adults, but pediatric use is not established, and caution is required when prescribing to patients with uncharacterized renal or hepatic function.

What should I know about interactions with other medicines?

Taxofen's interaction profile is primarily defined by agents that affect its concentration in the body and those that increase the risk of bleeding.

Pharmacokinetic Interactions (Drug Concentration)

  • Combined P-gp and Strong CYP3A Inhibitors: The concomitant use of medicinal products that are strong inhibitors of both P-glycoprotein (P-gp) and Cytochrome P450 3A4 (CYP3A4) is officially avoided. This combination significantly increases Taxofen exposure, which raises the risk of major bleeding complications.
  • Combined P-gp and Strong CYP3A Inducers: Concomitant use with strong combined P-gp and CYP3A4 inducers (e.g., Rifampicin) is also avoided. These agents substantially reduce Taxofen exposure, which may lead to reduced efficacy and an increased risk of thromboembolic events.

Pharmacodynamic Interactions (Bleeding Risk)

  • Other Anticoagulants: The coadministration of Taxofen with other systemic anticoagulants (e.g., Warfarin, Unfractionated Heparin, LMWH derivatives) should generally be avoided due to the significantly increased risk of bleeding.
  • Agents Affecting Hemostasis: Caution is required when using Taxofen concomitantly with medicines that also affect platelet function or clotting, such as Non-Steroidal Anti-inflammatory Drugs (NSAIDs), platelet inhibitors (e.g., Aspirin, Clopidogrel), and SSRI/SNRI antidepressants. This is due to an additive effect that increases the overall bleeding risk.

Mechanism of Action

Selective Estrogen Receptor Modulation (SERM)

Taxofen's mechanism is defined by its role as a Selective Estrogen Receptor Modulator (SERM), acting primarily through its metabolite, Endoxifen, which competitively binds to nuclear Estrogen Receptors (ERs). This competitive binding either blocks (antagonizes) the proliferative action of natural estrogen in certain tissues or acts as a partial agonist (stimulator) in others, establishing a tissue-specific effect profile.

Disruption of Cellular Growth Signals

The antagonistic action of Taxofen prevents the ER from initiating the transcription of estrogen-responsive genes that drive cellular division, resulting in the accumulation of cells in the G0/ G1 phases of the cell cycle. This mechanism engages the humoral pathway to produce cellular growth inhibition in estrogen-sensitive cells, thereby reducing estrogen-driven proliferation signals at the tissue level.

Alteration of Systemic Hormone Feedback

By blocking Estrogen Receptors in the central nervous system, Taxofen interferes with estrogen's normal negative feedback loop on the Hypothalamic-Pituitary-Gonadal (HPG) axis. This interference leads to a secondary physiological consequence of increased circulating levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), altering systemic endocrine signaling.

Dosage and Administration Information

Taxofen (Tamoxifen Citrate) is strictly an oral medication, available in two dosage forms: a tablet (commonly 10 mg and 20 mg strengths) and an oral solution. This defines the sole administration route for all usage protocols. The tablets must be swallowed whole with liquid, while the oral solution is a ready-to-use liquid formulation.

The standard adult daily dose is 20 mg. For certain long-term management contexts, the total daily dose may range up to 40 mg. The frequency pattern is established as daily; a total daily dose exceeding 20 mg is administered in divided doses (e.g., twice daily). A key administration condition is that the medication may be taken with or without food, allowing flexibility in the daily schedule.

Taxofen is prescribed as a long-term course, typically standardized for a duration of five years in the adjuvant setting, though the total course may be extended up to ten years. The general adult dosing regimen is consistent for older adults, and there are no defined specific dose adjustments for individuals with hepatic or renal impairment. Furthermore, administration is not recommended for the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Taxofen (Tamoxifen Citrate)

This overview summarizes the official research conducted for Taxofen, describing the types of studies that have been completed and what they have examined, according to governmental and peer-reviewed scientific sources. Research does not determine whether an individual will respond similarly, as findings describe patterns observed in the studies and not personal outcomes.


Evidence for Use in Early-Stage Hormone-Sensitive Disease

The research base for using Taxofen as a therapy following initial treatment for Estrogen Receptor-Positive (ER+) disease is built upon numerous studies. Scientists have conducted large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies explored how long-term outcomes evolved in large populations of patients after primary treatment. Outcomes monitored included outcomes reflecting disease progression and overall survival.

Research describes patterns observed in the studies related to outcomes reflecting disease progression for those with ER-positive tumors. Data show patterns related to these outcomes in observation periods well beyond the typical five years of treatment. Research is ongoing regarding the optimal duration of therapy for some individuals, and data for certain groups remain insufficient.


Evidence for Risk Reduction and Precursor Conditions

Taxofen was also evaluated in studies focusing on risk management. Scientists conducted large, controlled trials that compared Taxofen against a placebo (an inactive pill) in populations assessed as being at a statistically high likelihood of developing the condition. The study outcomes examined included the occurrence of a new condition.

Research highlights changes measured during the study period, indicating that the populations observed was associated with patterns of symptom change compared to the placebo groups. Studies also explored similar patterns in the use of Taxofen for patients with Ductal Carcinoma In Situ (DCIS), a non-invasive precursor condition, monitoring outcomes related to recurrence or new disease occurrence.


Key Limitations and Research Gaps

Despite the volume of research, certain areas of investigation contain limitations or remain uncertain. The evidence quality varies across studies, particularly in older or smaller trials. Data for certain subgroups defined by complex genetic markers remain insufficient. Comparative evidence is lacking for certain head-to-head comparisons, and research is ongoing to better define the long-term impact on functional measures and quality of life.

Key Studies & References

  1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials
  2. NSABP BCPT (P-1) Trial: Tamoxifen for preventing breast cancer—Initial and long-term results of the National Surgical Adjuvant Breast and Bowel Project BCPT-1
  3. Tamoxifen Citrate Tablets USP FDA Label (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Taxofen (FAQ)


Q: How quickly does Taxofen start working?

Taxofen is designed for long-term management rather than immediate relief. The active substance in the body, known as endoxifen, requires time to reach concentrations where it can exert its described pharmacological effects. Official prescribing information indicates that the active metabolite typically reaches its steady-state concentration after approximately 3 to 4 months of continuous daily treatment.


Q: How long do the effects of Taxofen last?

Studies on how the body processes the medicine indicate that Taxofen and its active metabolite remain in the body for a long time. The half-life of the active metabolite is approximately two weeks. Due to the long half-life, the presence of the active substance in the body is expected to persist for several weeks after administration of the medicine is discontinued.


Q: Is it okay to take Taxofen with food?

Yes, official administration instructions clearly state that Taxofen can be taken either with or without food. Some patient information indicates that taking the medicine with food may assist in mitigating common gastrointestinal side effects, such as nausea.


Q: Can I take Taxofen if I am on blood pressure medication?

Regulatory documents advise caution when combining Taxofen with any medication that significantly affects certain liver enzymes, such as CYP3A4, because this can change how much Taxofen is in the body. The importance of reviewing potential interactions with a healthcare professional is noted in regulatory information, even for common medications.


Q: What happens if I drink alcohol while taking Taxofen?

There is no specific contraindication against alcohol noted in the official product labeling. However, some clinical resources suggest that consuming alcohol could potentially worsen common side effects of Taxofen, such as nausea or fatigue. Some clinical sources note that alcohol consumption has been described as potentially increasing estrogen levels, which could theoretically affect the drug’s intended selective action.


Q: Can Taxofen affect birth control pills?

Official guidance for women who can become pregnant states they must use effective, non-hormonal contraception while taking Taxofen. Due to the way Taxofen works as an endocrine-targeting drug, use of hormonal birth control methods is generally considered inconsistent with the treatment profile and is therefore officially restricted.


Q: Does Taxofen affect my ability to drive or operate machinery?

Regulatory documents note that common side effects associated with Taxofen, such as headache, fatigue, and dizziness, may impair a person's ability to drive or use heavy machinery safely. Regulatory documents describe that individuals should be informed about these potential effects before engaging in activities like driving or operating machinery.


Q: Can Taxofen be crushed or split?

The official guidance for the tablet form of Taxofen states that it must be swallowed whole with liquid. To maintain the intended release and for handling purposes, official instructions state that the tablets are not to be chewed, split, or crushed before being swallowed.


Q: Does Taxofen cause weight gain or loss?

Data from clinical studies show that both weight gain and weight loss have been reported as adverse reactions associated with Taxofen. According to official clinical trial data, weight loss may be reported with a slightly higher frequency than weight gain among those taking the medication.


Q: Is it normal to feel tired after taking Taxofen?

Fatigue, or feeling generally tired, is a frequently reported adverse reaction associated with Taxofen therapy. Official documents list fatigue as a Common or Very Common side effect, depending on the specific study or population examined. It is listed as a frequently observed effect in official documents.


Q: Can Taxofen cause stomach problems?

Gastrointestinal issues are among the documented side effects of Taxofen. Nausea is listed as a Very Common reaction, and other adverse reactions such as abdominal pain, constipation, and diarrhea are also listed as Common in official prescribing information.


Q: What is the maximum duration of use recommended in the official documents for Taxofen?

The official use protocols for Taxofen describe treatment courses that typically start at five years. The total duration of therapy may be extended up to ten years, with the decision on the total duration of therapy described as being in accordance with established medical guidelines and individual treatment protocols.


Q: Can Taxofen cause problems with vision?

Yes, regulatory warnings state that Taxofen is associated with rare adverse reactions that affect the eye, including cataracts and optic neuropathy. The risk of developing cataracts is noted to increase with the duration of the medicine's administration, according to official safety information.


Q: What part of the body does Taxofen primarily target?

Taxofen is classified as a Selective Estrogen Receptor Modulator (SERM). Its main action is to target the Estrogen Receptors (ERs) found in cells across various tissues, including the breast and uterus, to modulate the cell's response to the hormone estrogen.


Q: Is Taxofen a type of painkiller?

No, Taxofen is not classified as a painkiller (analgesic). It belongs to a pharmacological class known as a Selective Estrogen Receptor Modulator (SERM). Its mechanism is to selectively block or modulate the actions of the hormone estrogen in certain tissues.


Q: Does Taxofen interact with common cold medicines?

Official warnings cover the risk of interaction with certain drug classes often found in cold and flu products, such as NSAIDs, which may increase the risk of bleeding. Caution is also advised regarding agents that affect how Taxofen is processed by the liver. Regulatory information advises that potential combinations should be reviewed.


Q: How long has Taxofen been available?

The active ingredient in Taxofen, tamoxifen, has a long history of use. The brand name version received initial FDA approval in the late 1970s or early 1980s. Since then, it has been widely used and studied for its approved indications.


Q: Are there foods I should avoid while taking Taxofen?

Official drug labeling states that Taxofen can be taken with or without food. However, because the medicine is processed by a liver enzyme called CYP3A4, some clinical references advise caution regarding the consumption of large quantities of grapefruit or grapefruit juice, as these can affect this enzyme.


Q: Why does Taxofen have a specific warning about certain pre-existing conditions?

Official regulatory documents include explicit contraindications and warnings concerning a patient's history of specific thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Regulatory documents note that the use of Taxofen has been associated with patterns of increased risk for these events in some populations.


Q: What should I do if I forget to take my Taxofen dose?

Official instructions provide specific guidance for managing a missed dose. These instructions clarify when to take the dose upon remembering it versus when to skip it entirely and continue the original schedule, emphasizing that a double dose should not be taken.


Q: Do the side effects of Taxofen go away over time?

Official documents do not make a general statement about all side effects resolving over time. However, some specific effects, like a temporary worsening of symptoms known as a tumor flare, are documented as generally subsiding rapidly after starting treatment. Conversely, the risk of other issues, such as cataracts, is noted to increase with the duration of use.


Q: Can Taxofen interact with herbal supplements?

Official drug labels warn of potential interactions with any agent that strongly affects the CYP2D6 and CYP3A4 liver enzymes. Since some common herbal supplements are known to interfere with these enzymes, regulatory information advises that the use of herbal products should be reviewed, particularly if they are known to affect CYP enzymes.


Q: Is Taxofen the same as [Name of similar drug, e.g., 'Drug X']?

Taxofen belongs to the drug class known as a Selective Estrogen Receptor Modulator (SERM). While there are other medicines that fall into this same class, regulatory documents describe Taxofen as a distinct chemical entity with its own specific safety and pharmacological profile.


Q: What is the difference between Taxofen and other drugs used for the same purpose?

Taxofen is chemically classified as a Selective Estrogen Receptor Modulator (SERM). Its unique profile is defined by how it selectively blocks the effects of estrogen in some tissues while acting as a weak stimulator in others. This selective action is described in official documentation.


Q: Why do some people use Taxofen for conditions other than its main use?

Official regulatory documents define the only approved uses for Taxofen, which are specific conditions related to certain hormone-sensitive diseases. The medicine is intended to be used only as described in the prescribing information for its approved indications.

How should Taxofen be stored and disposed of?

Storage & Disposal Scope

Labeled Storage Temperature Requirements: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F) .
Light/Moisture Protection Requirements: Protect from light and moisture; container must be kept tightly closed .
Stability After Opening/Reconstitution (if applicable): The oral solution must be discarded three months after the bottle is first opened .
Handling Requirements: The oral solution must not be refrigerated or frozen .
Packaging-Related Storage Rules (if applicable): Must be stored in the original container to protect from light .
Disposal Instructions (as documented in government sources): Do not dispose of by flushing down the toilet or putting in household trash; follow local pharmaceutical waste procedures .
Environmental or Controlled-Waste Disposal Requirements (if applicable): Classified as a hazardous medicinal product (NIOSH) .
Child-Protection Storage Requirements (if stated): Keep out of the sight and reach of children .

Storage/Disposal Classifications (High-Level)

Storage condition type: Controlled Room Temperature / Protect from Light / Tightly Closed Container
In-use stability classification (as defined in official documents): Limited (3 months after opening for oral solution)
Regulatory basis (EMA / FDA / etc.): FDA DailyMed, Soltamox Prescribing Information, NIOSH/CDC
Storage-context constraints (as defined in official documents): Should not exceed 30 C; Liquid form should not be refrigerated or frozen; Must be stored in original packaging.

Connection to the overall storage/disposal profile: Regulatory documents mandate that the product's chemical stability is maintained by adherence to a strict Controlled Room Temperature range and specific protection from light and moisture. Storage constraints ensure product integrity, while the mandatory instruction to keep the product out of the sight and reach of children addresses public safety. The classification as a hazardous drug dictates that disposal must be handled via controlled pharmaceutical waste channels to prevent environmental contamination, rather than through domestic waste systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Taxofen found in:

A-Z Index: